Segall Bryant & Hamill LLC acquired a new position in Aceto Co. (NASDAQ:ACET) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 173,896 shares of the company’s stock, valued at approximately $1,322,000. Segall Bryant & Hamill LLC owned approximately 0.56% of Aceto as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the stock. BlackRock Inc. raised its stake in Aceto by 1.2% in the first quarter. BlackRock Inc. now owns 4,087,319 shares of the company’s stock worth $31,064,000 after buying an additional 47,742 shares in the last quarter. Royce & Associates LP raised its stake in Aceto by 18.7% in the fourth quarter. Royce & Associates LP now owns 1,109,995 shares of the company’s stock worth $11,466,000 after buying an additional 175,052 shares in the last quarter. Citadel Advisors LLC raised its stake in Aceto by 66.9% in the first quarter. Citadel Advisors LLC now owns 425,616 shares of the company’s stock worth $3,235,000 after buying an additional 170,560 shares in the last quarter. Two Sigma Investments LP raised its stake in Aceto by 537.8% in the fourth quarter. Two Sigma Investments LP now owns 343,005 shares of the company’s stock worth $3,543,000 after buying an additional 289,225 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in Aceto by 66.5% in the fourth quarter. Two Sigma Advisers LP now owns 266,154 shares of the company’s stock worth $2,749,000 after buying an additional 106,300 shares in the last quarter. 70.71% of the stock is owned by institutional investors.
NASDAQ ACET opened at $4.02 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.12. Aceto Co. has a 12-month low of $2.22 and a 12-month high of $17.10. The firm has a market capitalization of $124.08 million, a price-to-earnings ratio of 3.38 and a beta of 1.65.
Aceto (NASDAQ:ACET) last released its quarterly earnings results on Thursday, May 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.22). Aceto had a positive return on equity of 7.93% and a negative net margin of 28.23%. The firm had revenue of $186.00 million during the quarter. During the same quarter in the prior year, the company earned $0.39 earnings per share.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 22nd. Shareholders of record on Friday, June 8th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, June 7th. Aceto’s dividend payout ratio is currently 3.36%.
A number of equities analysts recently commented on ACET shares. Canaccord Genuity downgraded shares of Aceto from a “buy” rating to a “sell” rating and set a $13.00 price objective for the company. in a research note on Thursday, April 19th. Craig Hallum lowered shares of Aceto from a “hold” rating to a “sell” rating in a report on Thursday, April 19th. Four research analysts have rated the stock with a sell rating and one has issued a hold rating to the stock. The stock has a consensus rating of “Sell” and an average price target of $2.00.
Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products, and specialty chemicals. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals.
Receive News & Ratings for Aceto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aceto and related companies with MarketBeat.com's FREE daily email newsletter.